JuvDataScience Lavender Cells Background


Rapidly improving the development of new drugs.

Artificial intelligence and machine learning will drive incredible efficiency and effectiveness in drug development and speed to market.
JuvDataScience People in a Lab

About JuvDataScience

Our strategic investments in several innovative ML/AI and data science companies will allow our development teams to identify unexpected synergistic drug combinations, repurpose existing drugs, discover novel drug targets, and accelerate opportunities into the clinic. We will use these capabilities to impact our own projects as well as new partnerships. This is one of our key competitive advantages as we reduce the cost and increase the speed with which new medicines get to patients.

In the News

Relation Therapeutics

Longevity Technology: 'Relation-Mila collaboration wins $1.3m Gates Foundation Award to fight COVID-19'

Relation Therapeutics and Mila, the Montreal-based AI research institute are collaborating on a new project targeting the development of COVID-19 therapeutics funded by the Bill & Melinda Gates Foundation.

September 1, 2020

Read More

G3 Therapeutics and Juvenescence form Juvenomics

Juvenescence Limited and G3 Therapeutics announced the formation of Juvenomics Limited, a joint venture between the two parent companies.

June 1, 2020

Read More
Insilico Medicine

Nature Biotech: ‘Deep learning enables rapid identification of potent DDR1 kinase inhibitors’

Insilico Medicine, a Juvenescence partner, recently highlighted their ability to use deep learning for de novo small-molecule design in Nature Biotech.

September 20, 2019

Read More
Contact Us
We are here to help answer any questions you might have.